

Original Research

Dynamic Changes in Airway Microbiota and Immune Homeostasis in Patients With COPD and the Implications for Nursing Management

Yao Zhong, MD¹ Meihua Wang, MD¹ Qunqun Zhu, MD¹

Abstract

Objectives: The objectives of this study were to investigate changes in airway microbiota and immune markers across chronic obstructive pulmonary disease (COPD) stages and their associations with clinical phenotypes and nursing factors, providing a basis for precision nursing.

Methods: A total of 284 stable COPD patients (Global initiative for chronic Obstructive Lung Disease [GOLD] grades 2–3) were enrolled. Sputum and clinical data were collected at baseline (T0), exacerbation (T1), and recovery (T2). Microbiota structure was analyzed via 16S ribosomal RNA sequencing, and levels of immune markers such as interleukin-8 (IL-8) and IL-1 β were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed by integrating clinical scale scores and nursing adherence data.

Results: At T1, airway microbial α diversity was remarkably lower than at T0 and T2 ($p < 0.01$). The relative abundances of *Haemophilus* and *Prevotella* increased, while those of *Veillonella* and *Lactococcus* decreased ($p < 0.01$). Levels of IL-8, IL-1 β , and tumour necrosis factor α were elevated, and secretory leukocyte protease inhibitor levels were reduced at T1 ($p < 0.01$). Notable correlations were found between microbiota and immune markers (e.g., *Haemophilus* abundance with IL-8 levels, $r = 0.52$, $p < 0.01$), and these were positively associated with clinical scores such as the COPD Assessment Test and St George's Respiratory Questionnaire ($p < 0.05$). Patients with $>80\%$ inhaler adherence and regular breathing exercises/nutrition had higher microbial diversity and attenuated inflammation ($p < 0.05$).

Conclusions: The airway microbiota-immune axis in COPD patients demonstrates a disease stage-dependent imbalance, characterized by microbial dysbiosis and enhanced pro-inflammatory responses during acute exacerbation. Good nursing adherence can modulate this axis's homeostasis, offering novel targets for precision nursing.

1. Department of Respiratory Medicine, Hangzhou Xixi Hospital, Hangzhou City, Zhejiang Province, China

Abbreviations:

AECOPD=acute exacerbation of COPD; **BMI**=body mass index; **CAT**=COPD Assessment Test; **CI**=confidence interval; **COPD**=chronic obstructive pulmonary disease; **ELISA**=enzyme-linked immunosorbent assay; **FEV₁ %pred**=forced expiratory volume in 1 second percentage predicted; **GOLD**=Global initiative for chronic Obstructive Lung Disease; **IL**=interleukin; **IQR**=interquartile range; **LDA**=linear discriminant analysis; **LefSe**=linear discriminant analysis effect size; **LL-37**=cathelicidin; **mMRC**=modified Medical Research Council dyspnea scale; **PCoA**=principal coordinates analysis; **PCR**=polymerase chain reaction; **PERMANOVA**=permutational multivariate analysis of variance; **QoL**=quality of life; **rRNA**=ribosomal RNA; **SD**=standard deviation; **SGRQ**=St George's Respiratory Questionnaire; **SLPI**=secretory leukocyte protease inhibitor; **TNF- α** =tumour necrosis factor α

Funding Support:

This work was supported by Hangzhou Xixi Hospital.

Citation:

Zhong Y, Wang M, Zhu Q. Dynamic changes in airway microbiota and immune homeostasis in patients with COPD and the implications for nursing management. *Chronic Obstr Pulm Dis*. 2026;13(5):373-385. doi: <https://doi.org/10.15326/jcopdf.2026.0799>

Publication Dates:

Date of Acceptance: July 16, 2026

Published Online Date: July 28, 2026

Address correspondence to:

Qunqun Zhu, MD
Department of Respiratory Medicine Nurse
Hangzhou Xixi Hospital
No. 2, Hengbu Street
Xihu District, Hangzhou City, Zhejiang Province
310063, China
Phone: +86-13646831297
Email: qunqunzhu8566@163.com

Keywords:

chronic obstructive pulmonary disease; airway microbiota; immune homeostasis; nursing management; acute exacerbation

This article has an online supplement.

Introduction

Chronic obstructive pulmonary disease (COPD) is a global public health problem because of its high prevalence, disability, and death rates, which together place a heavy burden on health.¹ Acute exacerbations of COPD (AECOPDs) are a key stage of the disease. They bring a faster loss of lung function and worse breathing symptoms—cough, sputum, and dyspnea—as well as more hospital visits and readmissions. Together, these lead to a worse quality of life for patients. Therefore, a better knowledge of AECOPD mechanisms and better nursing care strategies are very important to improve COPD outcomes. Although traditional concepts about infection and inflammation still prevail, new microbiome studies show that the lungs are not sterile. The microbes living there have a key role in keeping immune balance and in disease progression.^{2,3}

Recent microbiome research has revealed that the lungs harbor a resident microbiota that plays a key role in maintaining immune homeostasis.^{2,3} In healthy conditions, a dynamic balance exists between the airway microbiota and the host immune system. However, this balance is disrupted in COPD patients. Studies show that even during stable periods, COPD patients exhibit reduced airway microbial diversity and altered community structure.⁴ This dysbiosis worsens during AECOPDs, often manifesting as an ecological disturbance with increased relative abundance of Proteobacteria.^{5,6} Such microbial imbalance actively drives airway inflammation. For example, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Pseudomonas aeruginosa* can activate pattern recognition receptors on epithelial cells, leading to NF- κ B pathway activation and release of pro-inflammatory cytokines such as interleukin (IL)-8, IL-1 β , and tumor necrosis factor alpha (TNF α).^{7,8} At the same time, immunomodulatory molecules like secretory leukocyte peptidase inhibitor (SLPI) may be suppressed, weakening host defenses.^{9,10} This bidirectional interaction network is called the "microbiota immune axis," and its imbalance is a core mechanism in COPD.¹¹

Current COPD nursing practice relies mainly on general guidelines, lacking precision guidance tailored to individual biological states.^{12,13} Significant interindividual differences exist in microbiota composition and immune function, and therefore, the same nursing interventions may produce different responses.¹⁴ Predicting AECOPDs using only clinical symptoms has limited accuracy, and biomarkers are needed to improve prediction.¹⁵⁻¹⁷

Consequently, this study aims, through a large-scale prospective cohort design, to systematically characterize the dynamic trajectories of airway microbiota structure and key immune markers across different disease stages in COPD patients and to explore their associations with clinical symptoms, quality of life, and nursing behaviors. While this

observational design groups patients by disease stage rather than providing individualized treatment, the identification of stage-specific biomarker profiles provides a foundational step toward future individualized risk stratification. The findings are expected to provide clinical nurses with novel assessment perspectives and intervention targets, promoting the evolution of COPD nursing toward an individualized, biomarker-based precision management model (for a Graphical Abstract, click [here](#)).

Methods

Study Design and Ethical Approval

This research used a prospective observational cohort strategy. It was conducted in Hangzhou Xixi Hospital, Hangzhou City, China, a tertiary referral hospital with an established Department of Respiratory Medicine. The protocol was approved by the Ethics Committee of Hangzhou Xixi Hospital (approval number: HXH-EC-2025-011). Each participant provided written informed consent.

Study Participants

Participants were recruited from the respiratory outpatient clinics and inpatient departments of our hospital. A total of 284 eligible COPD patients were enrolled based on the conditions listed below.

Inclusion criteria included: (1) diagnosis of stable COPD meeting the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria (GOLD grades 2–3).¹³ Clinical stability was defined as the absence of an acute exacerbation for at least 6 weeks before enrollment, no systemic corticosteroids or antibiotics in the preceding 2 weeks, and stable symptoms with only normal daily fluctuations¹³; (2) age 40–80 years; (3) good communication skills and ability to cooperate with sample collection, questionnaire completion, and follow-up procedures; and (4) willingness to provide written informed consent.

Exclusion criteria included: (1) use of systemic antibiotics or immunosuppressants within the past 4 weeks; (2) comorbidities with other major respiratory diseases (e.g., lung cancer, bronchiectasis, asthma), immunodeficiency disorders, or active infections; (3) cognitive impairment, psychiatric disorders, or other conditions precluding study cooperation; and (4) severe dysfunction of the heart, liver, kidneys, or other vital organs.

Study Procedure and Data Collection

Data collection was conducted at 3 time points: T0 (stable baseline), T1 (acute exacerbation, within 48 hours of symptom worsening), and T2 (postrecovery stable period, 8–12 weeks after exacerbation). Acute exacerbation (T1

sampling) was defined as an acute worsening of respiratory symptoms beyond normal day-to-day variation—comprising increased dyspnea, cough, and/or sputum volume or purulence—requiring a change in the patient's regular medication, consistent with the Anthonisen criteria and GOLD 2023 guidelines.¹³

Clinical Baseline Data

Demographic information (age, sex, ethnicity, educational level, occupation, marital status, body mass index [BMI], residence status), smoking history (pack years, smoking status), medical history, family history, pulmonary function indices (forced expiratory volume in 1 second percentage predicted [FEV₁ %pred]), and frequency of acute exacerbations in the past year were collected.

Antibiotic Use and Smoking Confounders

Antibiotic use during the 4 weeks prior to each time point was recorded and categorized as none, oral, or intravenous. Smoking status was classified as current, former (quit >6 months), or never. Pack years were calculated. These variables were included as covariates in all multivariable models.

Sample Collection

Sputum samples were collected using a standardized hypertonic saline induction method. Briefly, participants inhaled 3% hypertonic saline via an ultrasonic nebulizer for up to 15 minutes. Expecterated sputum was visually separated from saliva using forceps under sterile conditions. Samples were processed within 2 hours: homogenization followed by centrifugation at 3000rpm for 10 minutes to separate supernatant and cell pellets. An additional high-speed centrifugation at 12,000×g for 10 minutes at 4°C was performed to ensure complete bacterial cell recovery. Cell pellets were collected as pellets after centrifugation and immediately stored at -80°C without any DNA preservative. All samples were thawed only once prior to DNA extraction.

Nursing Assessment Data

The COPD Assessment Test (CAT) was used to evaluate the impact of COPD on daily life. The modified Medical Research Council (mMRC) dyspnea scale assessed dyspnea severity. The St George's Respiratory Questionnaire (SGRQ) assessed quality of life. Inhaler adherence was assessed by dose counter and self-report; patients with ≥80% of prescribed actuations were classified as high adherers. Adherence to nonpharmacological interventions was defined as consistent practice of breathing exercises (pursed-lip or diaphragmatic breathing for ≥30 minutes/day, ≥5 days/week) combined

with a balanced nutritional plan verified by a dietitian (protein intake ≥1.0g/kg/day and BMI maintenance ≥20kg/m², assessed by a 3-day food record and nurse verification). Patients meeting all 3 criteria were called “high nursing adherence” (n=148, 52.11%). Those meeting ≤2 criteria were “moderate/low adherence” (n=136, 47.89%).

Antibiotic Data

At T1, antibiotic treatment data were recorded. Of 284 patients, 198 (69.7%) received antibiotics: amoxicillin clavulanate (n=89, 44.9%), levofloxacin (n=56, 28.3%), and azithromycin (n=53, 26.8%). Duration was 5–7 days for 167 patients (84.3%).

Laboratory Analyses

Microbiota Analysis

1. DNA extraction: DNA was extracted from cell pellets using QIAamp DNA Microbiome Kit (Cat. #51704, QIAGEN; Hilden, Germany). Mechanical lysis was performed using bead beating with 0.1mm glass beads in a TissueLyser II (QIAGEN) at 30Hz for 5 minutes, followed by enzymatic digestion with proteinase K at 56°C for 10 minutes, as specified in the kit protocol. The integrity and purity of the DNA were then evaluated by spectrophotometric measurement, wherein an A260/A280 ratio falling within 1.8 to 2.0 was required to proceed to sequencing. For each sequencing run, negative controls included: (1) a blank DNA extraction control (sterile water processed through the entire DNA extraction protocol), (2) a no template polymerase chain reaction (PCR) control, and (3) a mock community positive control (ZymoBIOMICS Microbial Community Standard, Zymo Research, Cat. #D6300; Irvine, California). Negative controls (extraction blanks) and positive controls (ZymoBIOMICS Microbial Community Standard) were included in each batch.
2. PCR amplification: Amplification of the 16S ribosomal RNA (rRNA) gene V3-V4 region was performed with primers 515F (5'-GTGYCAGCMGCCGCGGTAA-3') and 806R (5'-GGACTACNVGGGTWTCTAAT-3'). The thermal cycling program included an initial denaturation step (95°C for 5 min), 30 cycles of denaturation (95°C, 30 s), annealing (55°C, 30 s), and extension (72°C, 45 s), culminating in a final extension at 72°C for 10 min.
3. Sequencing and bioinformatics analysis: The PCR amplicons were size-verified by 1.5% agarose gel electrophoresis, then purified with AMPure XP beads (Beckman Coulter, Cat. #A63880; Brea, California) and quantified with Quanti-iT PicoGreen (Invitrogen, Cat. #P7589; Carlsbad, California). Libraries were

prepared with Nextera XT DNA Library Prep Kit (Illumina, Cat. #FC-131-1024; San Diego, California) and Nextera XT Index Kit v2 (Illumina, Cat. #FC-131-2001), then sequenced on the Illumina MiSeq platform using a v2 500-cycle kit (Cat. #MS-102-2003). Samples were randomized across 4 MiSeq runs (≈ 70 samples per run). Batch effect was assessed by permutational multivariate analysis of variance (PERMANOVA) ($R^2=0.02$, $p=0.18$). Bioinformatics analysis was performed using QIIME2 (v2023.7). Taxonomic assignment used the SILVA 138 99% OTU reference database trimmed to the 515F/806R region. Contaminant OTUs were removed using decontam (v1.10.0) with a prevalence threshold of 0.1. To define taxonomic units, sequences were clustered into OTUs at 97% sequence similarity. To obtain taxonomic profiles, OTUs were annotated using the SILVA database. Alpha diversity (Shannon, Chao1) and beta diversity (Bray-Curtis) were calculated using the q2-diversity plugin (QIIME2 v2023.7). Principal coordinates analysis (PCoA) was generated using scikit-bio (v0.5.8). Linear discriminant analysis effect size (LEfSe) analysis was performed using the galaxyhutlab online tool (LEfSe version 1.0). A STORMS checklist is provided as Supplementary File 1 in the online supplement.

Immune Marker Detection

Levels of IL-8, IL-1 β , TNF- α , SLPI, and cathelicidin (LL-37) in sputum supernatants were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems; Minneapolis, Minnesota) strictly according to the manufacturer's protocols. Absorbance was read at 450nm using a microplate reader, and concentrations were calculated based on standard curves.

Statistical Analysis

Statistical analyses were performed using SPSS (IBM; Armonk, New York) 26.0 and R 4.0.3 software (R Foundation; Vienna, Austria). Continuous variables were described as mean $\pm$ standard deviation or median (interquartile range [IQR]) based on distribution. Group comparisons were conducted using *t*-tests, Mann-Whitney U tests, or repeated-measures analysis of variance. Categorical variables were described as frequency (percentage), with group comparisons using the χ^2 test. Correlations between microbial indices, immune markers, and clinical scores were analyzed using Spearman's correlation. Multivariable linear mixed effects models were constructed to assess the independent association between microbiota indices (Shannon index, *Haemophilus* relative abundance) and immune markers, adjusting for age, sex, smoking status (current/former/never), FEV₁ %pred, and antibiotic use during exacerbation. Random intercepts

were included for each patient to account for repeated measures. Models were fitted using lme4 (v1.1 35) in R. *Haemophilus*, *Prevotella*, and *Veillonella* were selected for correlation analysis based on LEfSe (linear discriminant analysis > 4.0) and prior literature.⁵ For cross-sectional correlations, only one time point per patient was used (T1 for disease state, T2 for recovery). For longitudinal analyses, mixed effects models with patient random intercepts were used. Sensitivity analyses were performed: (1) excluding patients who received antibiotics within 2 weeks prior to T0 or T2 sampling; (2) stratifying analyses by smoking status; and (3) including pack years, current smoking status, and antibiotic use as fixed effects in mixed effects models. A *p*-value < 0.05 was considered statistically significant.

Results

Baseline Characteristics of Study Participants

The study ultimately included 284 COPD patients (GOLD grades 2–3). All patients completed follow-up at T0, T1, and T2 without serious adverse events. Participants were predominantly male (61.97%), with a mean age of 65.3 ± 8.4 years, a smoking history of 43.7 ± 15.8 pack years, and a median (IQR) of 2 (1–3) acute exacerbations in the past year. Pulmonary function assessment showed a mean FEV₁ %pred of $58.6 \pm 12.3\%$, consistent with GOLD grades 2–3 severity. Clinical evaluation at T0 revealed a mean CAT score of 12.4 ± 3.9 , mMRC grades primarily distributed as 2–3 (54.93%), and a mean SGRQ score of 36.3 ± 10.6 . Table 1 presents data stratified by sex with *p*-values (*t*-test or χ^2). No significant differences were found for age, FEV₁ %pred, or baseline CAT scores (all $p > 0.05$). Males had significantly higher smoking pack years (48.3 ± 16.2 versus 36.3 ± 12.5 , $p = 0.02$). Females had higher SGRQ scores (39.1 ± 10.9 versus 34.6 ± 10.0 , $p = 0.03$). Inhaler adherence ($> 80\%$) was similar between sexes (59.3% in females versus 59.7% in males, $p = 0.95$). Adherence to breathing exercises and balanced nutrition was also similar between sexes (51.7% in males versus 52.8% in females, $p = 0.86$). These differences are adjusted for in all multivariable models. Detailed demographic and clinical characteristics are presented in Table 1.

Longitudinal Dynamic Changes in Airway Microbiota

Alpha-Diversity Changes

Alpha-diversity analysis revealed significant differences in microbial richness and diversity across the 3 time points. At T1 (acute exacerbation), both the Shannon index (2.87 ± 0.53) and Chao1 index (189.62 ± 31.45) were markedly lower than at T0 (3.92 ± 0.61 , 256.37 ± 38.72) and T2 (3.78 ± 0.58 , 245.91 ± 36.28) ($F = 89.62$, 95.37 ,

Table 1. Demographic and Clinical Characteristics of Study Participants Stratified by Sex

Characteristic	Male (n=176)	Female (n=108)	P-value
Age (years)	65.1±8.5	65.7±8.3	0.56
Smoking Index (pack years)	48.3±16.2	36.3±12.5	0.02
FEV ₁ %pred	57.9±12.1	59.8±12.6	0.21
CAT Score at T0	12.2±3.9	12.6±3.8	0.39
SGRQ Score at T0	34.6±10.0	39.1±10.9	0.03
Inhaler Adherence >80% (n, %)	105 (59.7%)	64 (59.3%)	0.95
Breathing Exercises + Balanced Nutrition (n, %)	91 (51.7%)	57 (52.8%)	0.86

Data are mean±SD, n (%), or median (IQR)—P-values from *t*-test or χ^2 test.

FEV₁ %pred=forced expiratory volume in 1 second percentage predicted; CAT=COPD Assessment Test; SGRQ=St George's Respiratory Questionnaire; SD=standard deviation; IQR=interquartile range

respectively; both $p<0.01$). No significant difference was observed between T0 and T2 for either index ($t=1.89$ and 1.76 , respectively; both $p>0.05$), indicating a pronounced reduction in microbial diversity during exacerbation that tended to recover subsequently. The dynamic changes in α -diversity are shown in Figure 1(A, B).

Beta-Diversity Changes

PCoA based on Bray-Curtis distance demonstrated that the microbial community structure of sputum samples at T1 was significantly separated from those at T0 and T2 (PERMANOVA, $R^2=0.28$, $p<0.001$). In contrast, no significant separation was found between T0 and T2 ($R^2=0.03$, $p>0.05$). This indicates substantial remodeling of the airway microbiota community structure during acute exacerbation, with recovery to a state similar to the stable period. Beta-diversity analysis is shown in Figure 1C.

Changes in Relative Abundance of Key Microbial Genera

LEfSe analysis identified several microbial genera with significant differences across time points. At the genus level, the relative abundances of *Haemophilus* ($15.32\pm3.89\%$) and *Prevotella* ($18.76\pm4.23\%$) at T1 were significantly higher than at T0 ($5.89\pm1.96\%$, $7.21\pm2.15\%$) and T2 ($6.74\pm2.08\%$, $8.53\pm2.47\%$) ($F=102.56$, 118.73 , respectively; both $p<0.01$). Conversely, the relative abundances of *Veillonella* ($4.23\pm1.56\%$) and *Lactococcus* ($2.15\pm0.87\%$) at T1 were significantly lower than at T0 ($9.87\pm2.89\%$, $5.32\pm1.64\%$) and T2 ($8.96\pm2.64\%$, $4.89\pm1.52\%$) ($F=78.92$, 65.37 , respectively; both $p<0.01$). Details are shown in Figure 2A. The relative abundances of key differential microbial genera across the T0, T1, and T2 time points were computed and compared. To intuitively visualize these differences, a heatmap was generated. This comparative visualization is presented in Figure 2B.

Longitudinal Dynamic Changes in Immune Markers

ELISA results showed significant dynamic changes in immune

marker levels across disease stages. At T1, levels of pro-inflammatory cytokines IL-1 β (45.76 ± 11.28 pg/mL), IL-8 (126.83 ± 32.45 pg/mL), and TNF- α (67.35 ± 18.46 pg/mL) were substantially higher than at T0 and T2 ($p<0.01$). In contrast, the level of the immunomodulatory protein SLPI (32.45 ± 8.76 ng/mL) at T1 was notably lower than at T0 (58.16 ± 12.80 ng/mL) and T2 (53.78 ± 11.64 ng/mL) ($F=98.76$, $p<0.01$). No statistically significant difference was observed for LL-37 levels across the 3 time points ($F=2.37$, $p>0.05$). These results are presented in Figure 3.

Impact of Antibiotic Therapy on Microbiome Recovery

To assess whether antibiotic use at T1 influenced microbiome recovery at T2, we compared patients who received antibiotics ($n=198$) with those who did not ($n=86$). Patients receiving antibiotics showed a similar degree of Shannon index recovery from T1 to T2 ($\Delta\text{Shannon} = +0.91 \pm 0.42$) compared to nonantibiotic patients ($\Delta\text{Shannon} = +0.87 \pm 0.38$, $p=0.52$). However, antibiotic treated patients had lower *Veillonella* relative abundance at T2 ($7.12\pm2.34\%$) than nonantibiotic patients ($9.87\pm2.91\%$, $p=0.03$), suggesting a modest delayed recovery of this commensal genus.


Sensitivity Analyses

When excluding patients with recent antibiotic exposure ($n=42$ excluded), the Shannon index differences between T0, T1, and T2 remained significant ($p<0.01$). Smoking status stratified analyses showed similar microbiota patterns across current, former, and never smokers, though current smokers had lower baseline Shannon indices (3.42 ± 0.58 versus 3.89 ± 0.61 in never smokers, $p=0.04$).

Associations Among Microbiota, Immune Markers, and Clinical Phenotypes

Correlations Between Microbiota and Immune Markers

Spearman correlation analysis revealed a moderate positive correlation between the relative abundance of *Haemophilus* and IL-8 levels ($r=0.52$, $p<0.01$), and a moderate positive

Figure 1. Alpha Diversity of Sputum Microbiota Across T0 (Stable), T1 (Exacerbation), and T2 (Recovery)

(A) Shannon index; (B) Chao1 index. Boxes represent median and IQR; whiskers cover 1.5×IQR.

** $p < 0.01$ versus T0; ## $p < 0.01$ versus T1. (C) PCoA plot based on Bray-Curtis distances. Each point represents an individual sputum sample, colored by time point. Ellipses denote 95% confidence intervals for each group.

IQR=intequartile range; PCoA=principal coordinates analysis


correlation between *Veillonella* abundance and SLPI levels ($r = 0.41$, $p < 0.01$). Shannon index was negatively correlated with IL-8 ($r = -0.48$, $p < 0.01$), and Chao1 index was negatively correlated with TNF- α ($r = -0.42$, $p < 0.01$). In multivariable mixed effects models adjusting for age, sex, smoking status, FEV₁ %pred, and antibiotic exposure, *Haemophilus* abundance remained independently associated with IL-8 levels ($\beta = 0.38$, 95% confidence interval [CI]: 0.21–0.55, $p < 0.001$) and *Veillonella* abundance was independently associated with SLPI ($\beta = 0.33$, 95% CI: 0.16–0.50, $p = 0.001$). Scatter plots illustrating these correlations are shown in Figure 4(A–D).

Correlations Between Microbiota-Immune Indices and Clinical Scores


Shannon index showed significant negative correlations with concurrent CAT score ($r = -0.45$, $p < 0.05$) and mMRC grade ($r = -0.38$, $p < 0.05$). Patients with IL-8 > 55 pg/mL ($n = 89$) had significantly higher SGRQ scores (45.37 ± 11.89) compared to those with IL-8 ≤ 55 pg/mL (32.64 ± 9.76) ($t = 8.92$, $p < 0.01$). At T2, IL-8 levels were positively correlated with SGRQ scores ($r = 0.41$, $p < 0.05$). Analysis of microbiota-immune indices and clinical score correlations is shown in Figure 4(E–G).

Figure 2. Differential Bacterial Genera and Their Relative Abundance Across 3 Time Points


(A)



(B)



(A) LEfSe analysis. Histogram shows LDA scores of enriched taxa (LDA > 2.0).
**, $p < 0.01$ versus T0; ##, $p < 0.01$ versus T1. (B) Heatmap of normalized relative abundance of differential bacterial genera. Rows represent bacterial genera, columns represent patients grouped by time point; red=higher abundance, blue=lower abundance.
LEfSe=linear discriminant analysis effect size; LDA=linear discriminant analysis

Figure 3. Dynamic Changes in Sputum Immune Marker Levels in COPD Patients

Concentrations of pro-inflammatory cytokines IL-1β (A), IL-8 (B), TNF-α (C), SLPI (D), and LL-37 (E) were measured by ELISA. Data are shown as mean±SD. **, $p < 0.01$ versus T0; ##, $p < 0.01$ versus T1.

COPD=chronic obstructive pulmonary disease; IL=interleukin; TNF-α=tumour necrosis factor alpha; SLPI=secretory leukocyte protease inhibitor; LL-37=cathelicidin; ELISA=enzyme-linked immunosorbent assay

Impact of Nursing-Related Factors on Microbiota and Immune Indices


Analysis of nursing intervention adherence showed that patients with inhaler adherence $>80\%$ ($n=169$) exhibited significantly higher Shannon (3.91 ± 0.56) and Chao1 (251.37 ± 35.82) indices at T2 compared to those with adherence $\leq 80\%$ (3.42 ± 0.51 , 223.64 ± 33.15) ($t=7.89$, 6.74 , respectively; both $p < 0.05$). Patients who adhered to regular breathing exercises (≥ 30 minutes daily) and maintained balanced nutrition (protein ≥ 1.0 g/kg/day, BMI ≥ 20 kg/m²) ($n=148$) demonstrated a significantly smaller decline in SLPI levels during acute exacerbation (26.15 ± 7.64 ng/mL) compared to nonadherent patients (34.89 ± 9.12 ng/mL) ($t=8.23$, $p < 0.05$), along with lower peak levels of IL-8 and IL-1β. These results are depicted in Figure 5.

Discussion

Through longitudinal observation of 284 COPD patients, this study describes the evolving patterns of airway microbiota and immune markers across stable, acute exacerbation, and recovery phases, and preliminarily explores the influence of nursing behaviors on this "microbiota-immune axis." While these correlations do not establish causality, they provide observational support for the concept that microbial

dysbiosis and immune activation are linked phenomena in COPD exacerbation.¹¹ Acute exacerbation is characterized by reduced microbial diversity, expansion of *Haemophilus* and *Prevotella*, elevated pro-inflammatory cytokines (IL-8, IL-1β, TNF-α), and decreased SLPI.¹⁸ Although microbiota partially recovers postexacerbation, persistent inflammation correlates with worse quality of life, confirming dysbiosis as a key pathological feature driving local inflammation.^{19,20}

Within this axis, *Haemophilus* correlates positively with IL-8, while *Veillonella* abundance correlates positively with SLPI. Alpha diversity metrics, including Shannon and Chao1 indices, are inversely correlated with IL-8 and TNF-α, respectively. Notably, these genus-level correlations refine earlier transcriptomic and metatranscriptomic reports that implicated broad Proteobacteria expansion in NF-κB pathway activation.^{7,8,19} Pathogens may activate epithelial pattern recognition receptors to induce cytokine release,^{21,22} while commensals likely exert homeostatic effects via metabolites or barrier modulation.^{23,24} We acknowledge that the role of *Prevotella* in the airway is complex and context dependent. While our study found *Prevotella* abundance positively correlated with TNF α during exacerbation, other studies have demonstrated protective roles. Larsen et al reported that *Prevotella spp.* associated with healthy lungs induces limited neutrophilia and cytokine production compared to pathogenic Proteobacteria, suggesting a disease protective

Figure 4. Correlations of Airway Microbiota, Immune Markers, and Clinical Scores


(A-D) Correlations between microbiota indices and immune markers: (A) Shannon index versus IL-8; (B) Chao1 index versus TNF-α; (C) Haemophilus abundance versus IL-8; (D) Veillonella abundance versus SLPI. (E-G) Associations between alpha diversity/inflammation and clinical scores: (E) Shannon index versus CAT scores; (F) Shannon index versus mMRC grade; (G) SGRQ scores stratified by IL-8 level. Boxes show mean±SD, ** $p<0.01$.

IL=interleukin; TNF-α=tumour necrosis factor alpha; SLPI=secretory leukocyte protease inhibitor; CAT=COPD Assessment Test; mMRC=modified Medical Research Council; SGRQ=St George's Respiratory Questionnaire; SD=standard deviation

role.²⁴ Segal et al showed that *Prevotella* enriched lung microbiota in healthy individuals was associated with lower inflammatory cytokine profiles.²⁵ Bertelsen et al demonstrated that *Prevotella spp.* reduce *Pseudomonas aeruginosa* induced inflammation in cystic fibrosis bronchial epithelial cells.²⁶ These findings suggest that *Prevotella* may exert immunomodulatory functions under homeostatic conditions, while its expansion during COPD exacerbation may reflect oral microaspiration or loss of niche competition rather than purely pathogenic colonization.

The imbalance in this bidirectional interaction, particularly the co-occurrence of "pro-inflammatory flora" expansion and "beneficial flora" reduction during exacerbation, may collectively drive uncontrolled airway inflammation and tissue damage, thereby aggravating symptoms and accelerating lung function decline.²⁰ Notably, the significant reduction of SLPI during exacerbation in this study, with its level positively correlated with *Veillonella* abundance, suggests that this protease inhibitor may serve not only as an inflammatory marker but also as a key mediator in

Figure 5. Impact of Nursing Adherence on Airway Microbiota and Inflammatory Markers in COPD Patients



(A) Shannon index at T2 in patients with inhaler adherence >80% versus ≤80%. (B) Chao1 index at T2 by adherence group. (C) SLPI levels at T1 in patients adherent to breathing exercises/nutrition versus nonadherent. (D) Peak IL-8 levels at T1 by adherence. (E) Peak IL-1β levels at T1 by adherence. Data are presented as mean±SD, * $p < 0.05$.

COPD=chronic obstructive pulmonary disease; SLPI=secretory leukocyte protease inhibitor; IL=interleukin; SD=standard deviation

microbial modulation of host defense. These findings offer important new perspectives and implications for COPD nursing management.

Traditional nursing assessment relies on clinical symptoms, pulmonary function, and questionnaires,²⁷ lacking objective biological indicators. This study shows airway microbiota (e.g., *Haemophilus/Veillonella* ratio), alpha diversity measures (Shannon index), and inflammatory markers (IL-8, SLPI) dynamically reflect disease severity and correlate with CAT, mMRC, and SGRQ scores.²⁸ This supports integrating these biomarkers into nursing assessment. Simple, rapid detection methods (e.g., sputum or exhaled breath condensate) could identify high-risk patients for early warning and stratified management.^{29,30} For example, patients with persistently high IL-8 or low SLPI require intensified anti-inflammatory education, symptom monitoring, and inhaler adherence optimization.

Notably, this study offers a novel observational framework linking nursing adherence to microbiota-immune recovery. High inhaler adherence correlated with better microbial recovery, while regular breathing exercises and balanced nutrition attenuated SLPI decline and pro-inflammatory peaks during exacerbation. Furthermore, while previous work has focused on pharmacological or purely clinical determinants of exacerbation risk, our data

uniquely demonstrate that nonpharmacological nursing adherence (inhaler use, structured breathing exercises, and nutritional support) is independently associated with attenuated inflammatory peaks and faster microbial recovery. This aligns with emerging evidence that pulmonary rehabilitation and immunometabolic optimization can modulate airway ecology,³¹ but extends it by directly correlating nursing compliance metrics with microbiota-immune axis homeostasis. Standardized pharmacotherapy may improve microbiota via baseline inflammation control,³¹ while nonpharmacological interventions enhance airway clearance and immunometabolism to reduce dysbiosis-induced inflammation.³² Thus, nursing practice should prioritize integrated, continuous interventions: correct inhaler technique, individualized respiratory training, and nutritional screening to maintain airway microecological and immune homeostasis.³³ Together, these comparisons position our study not merely as a confirmation of dysbiosis in AECOPDs, but as a dynamic, behaviorally-informed model that bridges microbial ecology, immune regulation, and precision nursing practice.

These findings also support future targeted microbial modulation therapies. Given the links between specific genera (*Haemophilus*, *Prevotella*, *Veillonella*) and inflammation, inhaled probiotics, prebiotics, or phages

For personal use only. Permission required for all other uses.

could be investigated to reshape airway microbiota and mitigate inflammation.

This study has limitations, such as its single-center design and the exclusion of gut microbiota, which should be addressed in future research through multicenter collaboration and multi-omics integration. In addition, this study relied on 16S rRNA amplicon sequencing, which yields relative rather than absolute abundance estimates. Relative abundance data are subject to compositionality constraints and cannot directly reflect changes in total bacterial burden across disease states.³⁴ Future investigations should incorporate quantitative PCR targeting total bacterial 16S rRNA gene copy number alongside taxon-specific assays for key pathobionts such as *Haemophilus influenzae* and *Pseudomonas aeruginosa*,³⁵ to provide absolute abundance data and more precise quantification of pathobiont load during exacerbation and recovery. Given that species and strain-level differences within genera such as *Haemophilus* and *Prevotella* carry distinct clinical and immunological implications, future work using shotgun metagenomics, which also provides functional pathway annotation, will be necessary to resolve genus-level findings at the species level. Future research directions based on this study include developing microbiota-immune-based nursing risk assessment tools, validating personalized nursing interventions via randomized controlled trials, and exploring molecular pathways linking nursing measures to the microbiota-immune axis.

In summary, by revealing the dynamic interplay between airway microbiota and immune homeostasis in COPD patients, this study clarifies the pivotal role of the "microbiota-immune axis" in disease progression and closely links this biological insight to nursing practice. The findings support incorporating microbial and immune markers as a new dimension in nursing assessment and reinforce the importance of comprehensive nursing interventions in maintaining airway homeostasis and improving patient prognosis. This provides empirical evidence and a theoretical framework for advancing COPD nursing towards a more precise, individualized, and mechanism-informed direction.

Acknowledgements

Author contributions: YZ and QZ were responsible for the conceptualization of the manuscript. QZ supervised, provided project administration, and acquired funding. YZ was responsible for the methodology, and MW was responsible for data curation. YZ and MW were in charge of the investigation. YZ provided the formal analysis and MW provided the laboratory analysis. YZ wrote the original draft, and MW and QZ reviewed and edited the manuscript. All authors read and approved the final manuscript.

Data sharing statement: The 16S rRNA sequencing data generated during this study are not publicly available due to privacy restrictions but are available from the corresponding author on reasonable request. Other datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Declaration of Interest

The authors declare that they have no competing interests.

References

1. Bagdonas E, Raudoniute J, Bruzauskaite I, Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. *Int J Chron Obstruct Pulmon Dis*. 2015;10(1):995-1013. <https://doi.org/10.2147/COPD.S82518>
2. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. *PLoS One*. 2010;5(1):e8578. <https://doi.org/10.1371/journal.pone.0008578>
3. Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The microbiome and the respiratory tract. *Annu Rev Physiol*. 2016;78:481-504. <https://doi.org/10.1146/annurev-physiol-021115-105238>
4. Pragman AA, Lyu T, Baller JA, et al. The lung tissue microbiota of mild and moderate chronic obstructive pulmonary disease. *Microbiome*. 2018;6:7. <https://doi.org/10.1186/s40168-017-0381-4>
5. Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. *Eur Respir J*. 2016;47(4):1082-1092. <https://doi.org/10.1183/13993003.01406-2015>
6. Millares L, Pascual S, Montón C, et al. Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD Patients. *BMC Pulm Med*. 2019;19:112. <https://doi.org/10.1186/s12890-019-0867-x>
7. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. *Eur Respir J*. 2010;35(5):1039-1047. <https://doi.org/10.1183/09031936.00036709>
8. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol*. 2016;138(1):16-27. <https://doi.org/10.1016/j.jaci.2016.05.011>
9. Brown R, Dougan C, Ferris P, et al. SLPI deficiency alters airway protease activity and induces cell recruitment in a model of mucob obstructive lung disease. *Front Immunol*. 2024; 15:1433642. <https://doi.org/10.3389/fimmu.2024.1433642>
10. Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IκBα degradation without affecting phosphorylation or ubiquitination. *J Biol Chem*. 2002;277(37):33648-33653. <https://doi.org/10.1074/jbc.M203710200>
11. Budden KE, Shukla SD, Rehman SE, et al. Functional effects of the microbiota in chronic respiratory disease. *Lancet Respir Med*. 2019;7(10):907-920. [https://doi.org/10.1016/S2213-2600\(18\)30510-1](https://doi.org/10.1016/S2213-2600(18)30510-1)
12. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections--full version. *Clin Microbiol Infect*. 2011;17(Suppl 6):E1-E59. <https://doi.org/10.1111/j.1469-0691.2011.03672.x>
13. Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic Obstructive Lung Disease 2023 report: GOLD executive summary. *Eur Respir J*. 2023;61(4):2300239. <https://doi.org/10.1183/13993003.00239-2023>
14. D'Anna SE, Maniscalco M, Cappello F, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. *Ann Med*. 2021;53(1):135-150. <https://doi.org/10.1080/07853890.2020.1831050>
15. Waeijen-Smit K, DiGiandomenico A, Bonnell J, et al. Early diagnostic BioMARKers in exacerbations of chronic obstructive pulmonary disease: protocol of the exploratory, prospective, longitudinal, single-centre, observational MARKED study. *BMJ Open*. 2023;13(3):e068787. <https://doi.org/10.1136/bmjopen-2022-068787>
16. Ding HZ, Wang H, Wu D, et al. Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and 'frequent exacerbator' phenotype. *Mol Med Rep*. 2024;30(2):137. <https://doi.org/10.3892/mmr.2024.13261>
17. Lin Z, Jiang Y, Liu H, et al. Airway microbiota and immunity associated with chronic obstructive pulmonary disease severity. *J Transl Med*. 2025;23:962. <https://doi.org/10.1186/s12967-025-06986-2>
18. Tangedal S, Nielsen R, Aanerud M, et al. Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients. *PLoS One*. 2019;14(9):e0222449. <https://doi.org/10.1371/journal.pone.0222449>
19. Ramsheh MY, Haldar K, Esteve-Codina A, et al. Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. *Lancet Microbe*. 2021;2(7):e300-e310. [https://doi.org/10.1016/S2666-5247\(21\)00035-5](https://doi.org/10.1016/S2666-5247(21)00035-5)
20. Mayhew D, Devos N, Lambert C, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. *Thorax*. 2018;73(5):422-430. <https://doi.org/10.1136/thoraxjnl-2017-210408>
21. Larsen JM, Steen-Jensen DB, Laursen JM, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. *PLoS One*. 2012;7(2):e31976. <https://doi.org/10.1371/journal.pone.0031976>
22. Shuto T, Xu H, Wang B, et al. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKKα/β-IκBα and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. *Proc Natl Acad Sci U S A*. 2001;98(15):8774-8779. <https://doi.org/10.1073/pnas.151236098>
23. Ghorbani P, Santhakumar P, Hu Q, et al. Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. *Eur Respir J*. 2015;46(4):1033-1045. <https://doi.org/10.1183/09031936.00143614>

24. Larsen JM, Musavian HS, Butt TM, Ingvorsen C, Thysen AH, Brix S. Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal Prevotella spp., promote Toll-like receptor 2-independent lung inflammation and pathology. *Immunology*. 2015;144(2):333-342. <https://doi.org/10.1111/imm.12376>
25. Segal LN, Alekseyenko AV, Clemente JC, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. *Microbiome*. 2013;1:19. <https://doi.org/10.1186/2049-2618-1-19>
26. Bertelsen A, Elborn JS, Schock BC. Microbial interaction: Prevotella spp. reduce P. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells. *J Cyst Fibros*. 2021;20(4):682-691. <https://doi.org/10.1016/j.jcf.2021.04.012>
27. Mulvanny A, Beech A, Li J, Lea S, Singh D. Sputum cytokine repeatability in COPD. *Int J Chron Obstruct Pulmon Dis*. 2025;20:3779-3790. <https://doi.org/10.2147/COPD.S543956>
28. Sarioglu N, Hismiogullari AA, Bilen C, Erel F. Is the COPD assessment test (CAT) effective in demonstrating the systemic inflammation and other components in COPD? *Rev Port Pneumol (2006)*. 2016;22:11-17. <https://doi.org/10.1016/j.rppnen.2015.08.007>
29. Esther CR Jr, O'Neal WK, Anderson WH, et al. Identification of sputum biomarkers predictive of pulmonary exacerbations in COPD. *Chest*. 2022;161(5):1239-1249. <https://doi.org/10.1016/j.chest.2021.10.049>
30. Tateosian NL, Costa MJ, Guerrieri D, Barro A, Mazzei JA, Chuluyan HE. Inflammatory mediators in exhaled breath condensate of healthy donors and exacerbated COPD patients. *Cytokine*. 2012;58(3):361-367. <https://doi.org/10.1016/j.cyto.2012.03.006>
31. Melo-Dias S, Cabral M, Furtado A, et al. Responsiveness to pulmonary rehabilitation in COPD is associated with changes in microbiota. *Respir Res*. 2023;24:29. <https://doi.org/10.1186/s12931-023-02339-z>
32. Collins PF, Yang IA, Chang YC, Vaughan A. Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update. *J Thorac Dis*. 2019;11(Suppl 17):S2230-S2237. <https://doi.org/10.21037/jtd.2019.10.41>
33. Vega-Sánchez ÁE, Téllez-Navarrete NA, Pérez-Padilla R. Chronic obstructive pulmonary disease: perspectives for primary health care. *Rev Invest Clin*. 2019;71:55-63. <https://doi.org/10.24875/RIC.18002630>
34. Mirzayi C, Renson A, Genomic Standards Consortium, et al. Reporting guidelines for human microbiome research: the STORMS checklist. *Nat Med*. 2021;27:1885-1892. <https://doi.org/10.1038/s41591-021-01552-x>
35. Abdeldaim GM, Strålin K, Korsgaard J, Blomberg J, Welinder-Olsson C, Herrmann B. Multiplex quantitative PCR for detection of lower respiratory tract infection and meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis. *BMC Microbiol*. 2010;10:310. <https://doi.org/10.1186/1471-2180-10-310>